Close Menu

GenomeWeb

The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.

The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.

The Logix Smart Coronavirus COVID-19 test can now be sold as an IVD in markets that accept CE-marking as valid regulatory approval, the company said.

The firm's AmplideX Fragile X Dx and Carrier Screen Kit is intended to help diagnose fragile X syndrome and assess parental risk of having a child with the syndrome.

The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease.

Aiming to improve patient access to critical drugs and tests, a group of legislators have started a caucus to shore up bipartisan support for personalized medicine.

The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.

Aiming to improve patient access to critical drugs and tests, a group of legislators have started a caucus to shore up bipartisan support for personalized medicine.

Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.

Dec
06
Sponsored by
MNG Laboratories

Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers. 

Oct
25
Sponsored by
MNG Laboratories

Join us for a webinar presented by our Chief Medical Officer, Dr. Peter L. Nagy, to discuss the benefits of performing and analyzing genome and RNA sequencing together. The increased number of single nucleotide and copy number variants associated with genome sequencing are best interpreted with the help of joint parental testing and the assessment of the functional significance of intronic and regulatory changes with a functional test like the transcriptome.